Key result
In male patients with type 2 diabetes and left ventricular systolic dysfunction, 26 weeks of exenatide or insulin glargine had no significant effect on left ventricular ejection fraction (between-group p=0.11).
Why the study?
Does exenatide improve cardiac function, perfusion, and oxidative metabolism in type 2 diabetic patients with LV systolic dysfunction compared to insulin glargine?
Population
26 type 2 diabetic patients with LV systolic dysfunction and 10 healthy controls
Comparison
Exenatide for 26 weeks vs Insulin glargine for 26 weeks
Design
RCT, randomized
Follow-up
26 weeks
Authors
Loading...
Neither exenatide nor glargine alters LVEF despite metabolic gains; extends evidence that glycemic control may not improve cardiac function in this population.
RCT (n=26)
Open-label
1:1
No
Does exenatide improve cardiac function, perfusion, and oxidative metabolism in type 2 diabetic patients with LV systolic dysfunction compared to insulin glargine?
Absolute Event Rate: 52% vs 47%
p-value: p=0.11
In T2DM patients with LV systolic dysfunction, 26 weeks of treatment with exenatide or insulin glargine improved metabolic control but did not alter cardiac function, perfusion, or oxidative metabolism.
Chen et al. (2017) conducted an RCT in Type 2 diabetes mellitus with left ventricular systolic dysfunction (n=26). Exenatide vs. Insulin glargine was evaluated on Left ventricular ejection fraction (LVEF) after 26 weeks of treatment (p=0.11). In male patients with type 2 diabetes and left ventricular systolic dysfunction, 26 weeks of exenatide or insulin glargine had no significant effect on left ventricular ejection fraction (between-group p=0.11).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: